Regorafenib (Stivarga) for Metastatic Colorectal Cancer and GIST (online only)
Regorafenib (Stivarga) for Metastatic Colorectal Cancer and GIST (online only)
April 29, 2013 (Issue: 1415)
Regorafenib (Stivarga – Bayer), a multikinase inhibitor,
has been approved by the FDA for treatment of
patients with metastatic colorectal cancer previously
treated with multiple other regimens specified in the
labeling. It has also been...more
1. A Grothey et al. Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial. Lancet 2013; 381:303.
2. GD Demetri et al. Efficacy and safety of regorafenib for advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib (GRID): an international, multicentre, randomised, placebocontrolled, phase 3 trial. Lancet 2013; 381:295.
3. Wholesale acquisition cost (WAC). Source: $ource® Monthly (Selected from FDB MedKnowledge™) April 5, 2013. Reprinted with permission by FDB, Inc. All rights reserved. ©2013. www.fdbhealth.com/policies/drug-pricing-policy. Actual retail prices may vary.
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.
Would you like to read the rest of this article? Gain access below.
Subscribe
Subscriptions to
The Medical Letter on Drugs and Therapeutics include:
- Print version published and mailed biweekly (26 issues/year)
- Unlimited online access to current and past issues (1988 - present)
- Mobile App
- FREE online per issue CME/CE
Purchase this article:
Title: Regorafenib (Stivarga) for Metastatic Colorectal Cancer and GIST (online only)
Article code: 1415c
Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.
